Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, Welin M, Chattopadhyay S, Harms BD, Nielsen UB, Schoeberl B, Lugovskoy AA, MacBeath G.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7533-7542. doi: 10.1073/pnas.1819085116. Epub 2019 Mar 21.

PMID:
30898885
2.

MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.

Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA.

Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26.

3.

Lessons learned from quantitative dynamical modeling in systems biology.

Raue A, Schilling M, Bachmann J, Matteson A, Schelker M, Kaschek D, Hug S, Kreutz C, Harms BD, Theis FJ, Klingmüller U, Timmer J.

PLoS One. 2013 Sep 30;8(9):e74335. doi: 10.1371/journal.pone.0074335. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/ea0193d8-1f7f-492a-b0b7-d877629fdcee. Schelke, Max [corrected to Schelker, Max].

4.

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.

Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA.

Methods. 2014 Jan 1;65(1):95-104. doi: 10.1016/j.ymeth.2013.07.017. Epub 2013 Jul 18.

PMID:
23872324
5.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

6.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

7.

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B.

Methods Enzymol. 2012;502:67-87. doi: 10.1016/B978-0-12-416039-2.00004-5.

PMID:
22208982
8.

Systems biologists seek fuller integration of systems biology approaches in new cancer research programs.

Wolkenhauer O, Auffray C, Baltrusch S, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JE Jr, Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, Jaster R.

Cancer Res. 2010 Jan 1;70(1):12-3. doi: 10.1158/0008-5472.CAN-09-2676. Epub 2009 Dec 22.

9.

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB.

Sci Signal. 2009 Jun 30;2(77):ra31. doi: 10.1126/scisignal.2000352.

10.

Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions.

Harms BD, Bassi GM, Horwitz AR, Lauffenburger DA.

Biophys J. 2005 Feb;88(2):1479-88.

Supplemental Content

Loading ...
Support Center